Henderson Morley still in talks to divest ICVT asset
This article was originally published in Scrip
Henderson Morley has said it remains confident that its negotiations with KMS Therapeutics will result in a sale of its ICVT (Ionic Contra Viral Therapy) portfolio, as agreed in the letter of intent (LOI) signed earlier this year by KMS. However, Henderson Morley will remain in discussions with the unnamed non-European company that signed a previous LOI concerning ICVT in October last year. These discussions will continue until such time as the sale of ICVT is concluded, Henderson Morley noted.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.